Objective To investigate the changes in the expression of four and a half LIM domains 1 (FHL1) in breast neoplasm after neo-adjunct chemotherapy (NCT), and its clinical significance. Methods Expression of FHL1 in breast cancer before and after NCT (with docetaxel combined pirarubicin) was detected by immunohistochemical technique in 76 patients with breast neoplasm. Specimens of 69 cases had received NCT before, of them 63 cases were finally enrolled in present study, among them the specimens were obtained from 59 cases for cohort study. The positive rate and expression intensity of FHL1 before and after NCT were analyzed. Results The positive rate of FHL1 in breast cancer was 79. 7% before chemotherapy and 65.1% after chemotherapy. The expression of FHL1 was up-regulated in 17 patients, down regulated in 30 patients, and remained unchanged in 12 patients. The matched pair test showed that the expression of FHL1 significantly down regulated after NCT ( P<0.05). Conclusion NCT may down regulate the expression of FHLI, which may play a harmful effect on the prognosis of a part of patients with breast cancer.%目的 研究经新辅助化疗(NCT)的乳腺癌组织中抑癌基因FHL1表达的变化及临床意义.方法 对76例多西他赛联合吡柔比星新辅助化疗前后的乳腺癌标本进行FHL1检测,最终69例化疗前标本和63例化疗后检测结果 纳入评价,前后配对的标本共59例,对新辅助化疗前后FHL1的表达率和表达强度进行比较.结果 化疗前FHL1阳性率为79.7%,化疗后阳性率为65.1%.化疗后FHL1表达增强l7例,不变12例,下调30例,配对等级资料检验证明FHL1在化疗后表达降低,差异有统计学意义(P＜0.05).结论多西他赛加吡柔比星新辅助化疗后FHL1表达下降.新辅助化疗降低FHL1表达可能会对部分患者的预后产生不良影响.
展开▼
